Large-scale investigation supports modified classification system for pulmonary adenocarcinomas

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the 2023 World Conference on Lung Cancer in Singapore.

Dr. Thunnissen and colleagues conducted a case-control study involving resected adenocarcinomas measuring up to 3cm , the research evaluated the potential of a modified classification system. The modified classification factored in iatrogenic collapsedPathologists initially assessed the cases according to the WHO criteria and then underwent a tutorial, after which they scored the cases based on the modified classification.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Taiwan's lung cancer early detection program detects 85% of lung cancer cases at early phaseThe Taiwan National Lung Cancer Early Detection Program detected 85% of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
Source: medical_xpress - 🏆 101. / 51 Read more »

Taiwan National Lung Cancer Early Detection Program offers hope for saving lives through early diagnosisThe Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
Source: NewsMedical - 🏆 19. / 71 Read more »

Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »

Study aims to identify interventions to combat stigma associated with lung cancer and smoking-related respiratory diseasesThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLCThe International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.
Source: NewsMedical - 🏆 19. / 71 Read more »

Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Source: NewsMedical - 🏆 19. / 71 Read more »